Xeris Biopharma Holdings, Inc.
US ˙ NasdaqGS ˙ US98422E1038

SecurityXERS / Xeris Biopharma Holdings, Inc.
InstitutionQUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series
Latest Disclosed Ownership259,750 shares
Latest Disclosed Value $ 1,213,032
QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series reports 7.35% increase in ownership of XERS / Xeris Biopharma Holdings, Inc.

On August 26, 2025 - QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series filed a NPORT-P form disclosing ownership of 259,750 shares of Xeris Biopharma Holdings, Inc. (US:XERS) valued at $1,213,032 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 28, 2025 disclosing 241,971 shares of Xeris Biopharma Holdings, Inc.. This represents a change in shares of 7.35% during the quarter. The current value of the position is $1,605,255 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-08-26 2025-06-30 NP Xeris Biopharma Holdings EC US98422E1038 259,750 17,779 7.35 1,213 -8.66 0.0272
2025-05-28 2025-03-31 NP Xeris Biopharma Holdings EC US98422E1038 241,971 0 0.00 1,328 61.95 0.0319
2025-02-25 2024-12-31 NP Xeris Biopharma Holdings EC US98422E1038 241,971 -39,961 -14.17 820 2.12 0.0179
2024-11-26 2024-09-30 NP Xeris Biopharma Holdings EC US98422E1038 281,932 21,959 8.45 804 37.50 0.0152
2024-08-26 2024-06-30 NP Xeris Biopharma Holdings EC US98422E1038 259,973 24,264 10.29 585 12.31 0.0119
2024-05-28 2024-03-31 NP Xeris Biopharma Holdings EC US98422E1038 235,709 -17,554 -6.93 521 -12.61 0.0109
2024-02-26 2023-12-31 NP Xeris Biopharma Holdings EC US98422E1038 253,263 22,184 9.60 595 38.69 0.0127
2023-11-28 2023-09-30 NP Xeris Biopharma Holdings EC US98422E1038 231,079 0 0.00 430 -29.09 0.0112
2023-08-25 2023-06-30 NP Xeris Biopharma Holdings EC US98422E1038 231,079 26,542 12.98 605 81.68 0.0144
2023-05-26 2023-03-31 NP Xeris Biopharma Holdings EC US98422E1038 204,537 0 0.00 333 22.43 0.0089
2023-02-24 2022-12-31 NP Xeris Biopharma Holdings EC US98422E1038 204,537 0 0.00 272 -14.73 0.0075
2022-11-25 2022-09-30 NP Xeris Biopharma Holdings EC US98422E1038 204,537 0 0.00 319 1.59 0.0091
2022-08-25 2022-06-30 NP Xeris Biopharma Holdings EC US98422E1038 204,537 204,537 315 0.0087
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.